Brokerage : Shinhan Securities
Analyst : Minyong Eom, Seokhyeon Yoon
Investment Rating : BUY (Maintained)
Target Price : KRW 570,000 (Maintained)
Core Momentum : Execution of an KRW 870.0 Billion deal with Biogen just two months after the GSK agreement confirms shortened licensing deal cycles and mid-single digit royalty economics, with major catalysts lined up from April including J-code implementation and early June PGR rulings.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price KRW 570,000 (Maintained) (Upside potential of 49.66% based on the March 26, 2026 closing price of KRW 381,000)
- Valuation & Target Price Strategy: Maintains BUY rating and sector Top Pick. Target price will be updated using a Sum-of-the-Parts (SOTP) valuation once specific target assets are confirmed upon Biogen’s clinical trial initiations.
- Market Data: Market Cap KRW 20.40 Trillion / Shares Outstanding 53.5 Million (Floating Shares 79.6%) / 52-Week High KRW 559,000, Low KRW 317,500 / 60-Day Average Trading Value KRW 304.0 Billion / Foreign Ownership 13.8% / Major Shareholders: Soonjae Park and 4 affiliates 20.4%, Inwoo Hyung and 2 affiliates 5.1%
- Annual Financial Forecast (Shinhan Securities Estimates):
- 2025F: Revenue KRW 239.3 Billion, Operating Profit KRW 114.1 Billion (OPM 47.7%), Net Profit (Controlling) KRW 25.0 Billion, PER 967.3x, PBR 81.2x, ROE 8.7%, EV/EBITDA 205.1x
- 2026F: Revenue KRW 579.3 Billion, Operating Profit KRW 342.1 Billion (OPM 59.1%), Net Profit (Controlling) KRW 294.6 Billion, PER 69.8x, PBR 34.6x, ROE 66.1%, EV/EBITDA 58.2x
- 2027F: Revenue KRW 998.7 Billion, Operating Profit KRW 477.3 Billion (OPM 47.8%), Net Profit (Controlling) KRW 418.8 Billion, PER 49.1x, PBR 20.3x, ROE 52.2%, EV/EBITDA 41.0x
🚀 2. [Market Opportunities & Business Outlook]
- Biogen Licensing Agreement & Financial Terms:
- Signed an agreement with US-based Biogen valued at KRW 870.0 Billion for exclusive rights for two ALT-B4-based assets, plus options allowing development of up to three additional assets. Upfront payment stands at KRW 30.0 Billion, with an additional KRW 15.0 Billion recognized upon subsequent asset development initiation.
- Successfully resolved previous market concerns over royalty rates post-Keytruda SC disclosure, maintaining a favorable mid-single digit (4%–6%) royalty structure.
- The analyst estimates that potential candidate assets may include felzartamab SC (CD38 target), dapirolizumab pegol SC (CD40L target), and high-dose Leqembi SC (beta-amyloid target for Alzheimer’s disease).
- Qualitative Platform Expansion into Autoimmune & Neurodegenerative Diseases:
- Extends platform utility from oncology (mAbs, bispecifics, ADCs) into autoimmune disorders and neurodegenerative conditions (Alzheimer’s).
- Potential out-licensing of next-generation bispecifics (such as PD-1/VEGF) with mid-single digit royalties is expected to permanently resolve market anxieties regarding Keytruda SC’s ~2% royalty rate.
- Sequential Catalysts from April:
- April: Full-scale commercial prescription rollout of Keytruda SC in the US following permanent J-code implementation.
- May–June: Scheduled KOSPI market transfer listing.
- June 2: Final written decision from the US PTAB regarding Halozyme’s MDASE patent invalidation (PGR).
- June 9–11: World ADC Asia Summit presentation featuring world-first Enhertu SC Phase 1 clinical data.
- Q3: AstraZeneca’s Imfinzi SC Phase 1 clinical trial readouts expected.
📝 Editor’s Comment (Perspective)
The analyst views Alteogen as a subcutaneous drug delivery technology company that has successfully dispelled market concerns regarding royalty rates and deal momentum by executing back-to-back out-licensing deals with GSK in January and Biogen in March (confirming mid-single digit royalty structures), while broadening its reach from oncology into autoimmune and neurodegenerative diseases. The overarching perspective prioritizes the accelerating deal cadence, full-scale US commercial adoption of Keytruda SC under its new J-code in April, and major inflection points in early June—including the PTAB PGR ruling and Enhertu SC Phase 1 clinical readouts—over short-term price pullbacks.
To verify whether this investment thesis progresses as expected, investors should primarily monitor Keytruda SC prescription growth following April’s J-code rollout, the US PTAB’s final PGR written decision on June 2, Enhertu SC Phase 1 clinical data presented at the World ADC Asia Summit, and formal target asset confirmations upon Biogen’s clinical trial initiations. These developments can be verified through upcoming quarterly earnings releases, official company IR presentations, regulatory filings on DART/KRX, and global partner pipeline disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
